medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2011, Número 3

<< Anterior Siguiente >>

Neumol Cir Torax 2011; 70 (3)


Neumonía por Pneumocystis jirovecii en pacientes con VIH

Cortés-Télles A, Juárez HF, Peña MES

Idioma: Español
Referencias bibliográficas: 34
Paginas: 165-171
Archivo PDF: 210.43 Kb.


RESUMEN

La neumonía por Pneumocystis jirovecii se mantiene como una de las infecciones oportunistas que define con mayor frecuencia al síndrome de inmunodeficiencia adquirida, sobre todo en países con bajo ingreso económico, bajo estrato social y sin acceso universal a la terapia antirretroviral altamente activa o de gran actividad. Es una condición clínica que se manifiesta de forma insidiosa y progresiva habitualmente en un período de 2 a 4 semanas. Este aspecto favorece, en casos aislados, el desarrollo de insuficiencia respiratoria rápidamente progresiva que requiere el apoyo de ventilación mecánica y manejo en la unidad de cuidados intensivos. Avances tecnológicos han permitido reconocer de forma oportuna al microorganismo. Del mismo modo, se han identificado con mayor certeza las características biológicas, el espectro de presentación clínica, la presentación por imagen y el tratamiento. Por lo tanto, se requiere mantener un conocimiento constante sobre la evolución de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008;134:1287-1298.

  2. Powell K, Davis JL, Morris AM, Chi A, Bensley MR, Huang L. Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009;135:11-17.

  3. Rosen MJ, Narasimhan M. Critical care of immunocompromised patients: human immunodeficiency virus. Crit Care Med 2006;34(9 Suppl):245-250.

  4. Linden PK. Approach to the immunocompromised host with infection in the intensive care unit. Infect Dis Clin North Am 2009;23:535-556.

  5. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008;14(Suppl 3):15-21.

  6. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 2008;23:91-100.

  7. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 2010;24:107-138.

  8. Vanek J, Jirovec O. Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by Pneumocystis carinii. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1952;158:120-127.

  9. Frenkel JK. Pneumocystis jirovecii n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl Cancer Inst Monogr 1976;43:13-30.

  10. Rosen MJ. Pulmonary complications of HIV infection. Respirology 2008;13:181-190.

  11. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891-896.

  12. Wyder MA, Rasch EM, Kaneshiro ES. Quantitation of absolute Pneumocystis carinii nuclear DNA content. Trophic and cystic forms isolated from infected rat lungs are haploid organisms. J Eukaryot Microbiol 1998;45:233-239.

  13. Limper AH, Martin WJ 2nd. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest 1990;85:391-396.

  14. Huang L, Crothers K. HIV-associated opportunistic pneumonias. Respirology 2009;14:474-485.

  15. Huang L, Morris A, Limper AH, Beck JM. ATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: recent advances and future directions in Pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006;3:655-664.

  16. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999;104:1307-1317.

  17. Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol 1993;150:3932-3940.

  18. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009;301:2578-2585.

  19. Morris A, Lundgren JD, Masur H, et ál. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-1720.

  20. Hung CC, Chang SC. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother 2004;54:849-853.

  21. Boyton RJ. Infectious lung complications in patients with HIV/AIDS. Curr Opin Pulm Med 2005;11:203-207.

  22. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498.

  23. Vogel MN, Weissgerber P, Goeppert B, et ál. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jirovecii pneumonia. Swiss Med Wkly 2011;141:w13184.

  24. Tasaka S, Hasegawa N, Kobayashi S, et ál. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007;131:1173-1180.

  25. de Boer MG, Gelinck LB, van Zelst BD, et ál. b-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect 2011;62: 93-100.

  26. Boiselle PM, Crans CA Jr, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol 1999;172:1301-1309.

  27. Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med 1992;152:1390-1398.

  28. Feldman C. Pneumonia associated with HIV infection. Curr Opin Infect Dis 2005;18:165-170.

  29. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis pneumonia. N Engl J Med 1990;323:1500-1504.

  30. Fei MW, Kim EJ, Sant CA, et ál. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009;64:1070-1076.

  31. Japiassú AM, Amâncio RT, Mesquita EC, et ál. Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care 2010;14: R152.

  32. Cunha BA. Cytomegalovirus pneumonia: community-acquired pneumonia in immunocompetent hosts. Infect Dis Clin North Am 2010;24:147-158.

  33. Cortés A, Peña E, Vega R, Reyes G, Bautista E. Massive alveolar hemorrhage due to cytomegalovirus (CMV) and HIV infection. Med Intensiva 2011;35:126-129.

  34. López BQJC, Miro JM, Peña JM, et ál; Grupo de Estudio del SIDA 04/98. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-167.




2020     |     www.medigraphic.com